Over the last 15 years, there has been an evolution in the thinking of how tumors
grow and disseminate: from the earlier work where it was considered that the intrinsic
characteristics of the tumor largely determined the process to more recent work where
local and systemic inflammatory responses play a key role in disease progression and
survival in patients with cancer. Although the immune/inflammatory responses to cancer
are complex, it is clear that targeting the host immune/inflammatory responses (in
particular, innate/humoral responses) has considerable potential to improve outcomes
in patients with a variety of common solid tumors. There are a wide variety of agents
from the nonselective glucocorticoids to the selective Janus Activated Kinase/Signal
Transducer and Activator of Transcription (JAK/STAT) inhibitors that has considerable
therapeutic potential. They may be considered to act through a main signal transduction
mechanism, the interleukin-6/JAK/STAT pathway. This work heralds a new era in which
it will be important not only to treat the tumor but also to treat the host, so called
oncoimmunology.
Abbreviations:
JAK (Janus Activated Kinase), STAT (Signal Transducer and Activator of Transcription), EGF (epidermal growth factor), TGF-B (transforming growth factor beta), VEGF (vascular endothelial growth factor), TNF-a (tumour necrosis factor alpha), CRP (C-reactive protein), COX (cyclooxygenase), TNM (tumour node metastases), CD3 (Type I transmembrane protein found on T-lymphocytes), AOM-DSS (azoxymethane- dextran sodium sulphate)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Translational ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The hallmarks of cancer.Cell. 2000; 100: 57-70
- Hallmarks of cancer: the next generation.Cell. 2011; 144: 646-674
- The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis.Nat Cell Biol. 2014; 16: 717-727
- Cancer immunity and inflammation.in: Kerr The Oxford Textbook of Oncology. 3rd ed. Oxford University Press, 2015 (ISBN: 9780199656103, In press)
- Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.Nat Med. 2013; 19: 1625-1631
- Structural recognition and functional activation of FcgammaR by innate pentraxins.Nature. 2008; 456: 989-992
- C-reactive protein at the interface between innate immunity and inflammation.Expert Rev Clin Immunol. 2008; 4: 379-390
- Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients' adverse prognosis.PLoS One. 2012; 7: e30806
- The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer.Cancer Treat Rev. 2012; 38: 451-466
- Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop.J Pathol. 2011; 225: 438-447
- Optimization of the systemic inflammation-based Glasgow prognostic score: a Glasgow Inflammation Outcome Study.Cancer. 2013; 119: 2325-2332
- Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.Future Oncol. 2010; 6: 149-163
- Presence of tumoural C-reactive protein correlates with progressive prostate cancer.Prostate Cancer Prostatic Dis. 2011; 14: 122-128
- Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.Science. 2006; 313: 1960-1964
- The adaptive immunologic microenvironment in colorectal cancer: a novel perspective.Cancer Res. 2007; 67: 1883-1886
- The clinical utility of the local inflammatory response in colorectal cancer.Eur J Cancer. 2014; 50: 309-319
- Comment on ‘Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis’.Br J Cancer. 2014; 111: 2372
- Cancer-related inflammation and treatment effectiveness.Lancet Oncol. 2014; 15: e493-e503
- New clinical advances in immunotherapy for the treatment of solid tumours.Immunology. 2015; 145: 182-201
- Tumor associated macrophages and neutrophils in cancer.Immunobiology. 2013; 218: 1402-1410
- The immune contexture of primary and metastatic human tumours.Curr Opin Immunol. 2014; 27: 8-15
- Immune cell promotion of metastasis.Nat Rev Immunol. 2015; 15: 73-86
- Macrophages and therapeutic resistance in cancer.Cancer Cell. 2015; 27: 462-472
- Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.Immunity. 2013; 39: 782-795
- Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.Nat Immunol. 2010; 11: 889-896
- The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer.Ann Oncol. 2014; 25: 644-651
- Myeloid-derived cells are key targets of tumor immunotherapy.Oncoimmunology. 2014; 3: e28398
- Host response to colorectal cancer.ANZ J Surg. 2008; 78: 745-753
- Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer.Br J Cancer. 2007; 97: 1266-1270
- Routine clinical markers of the magnitude of the systemic inflammatory response after elective operation: a systematic review.Surgery. 2015; 157: 362-380
- Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis.Proc Natl Acad Sci U S A. 2006; 103: 12493-12498
- The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer.Crit Rev Oncol Hematol. 2013; 88: 218-230
- The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.Cancer Treat Rev. 2013; 39: 534-540
- Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer.Br J Cancer. 2013; 109: 131-137
- IL-6 and related cytokines as the critical lynchpins between inflammation and cancer.Semin Immunol. 2014; 26: 54-74
- Methotrexate is a JAK/STAT pathway inhibitor.PLoS One. 2015; 10: e0130078
- The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours.Br J Cancer. 2015; 113: 365-371
- JAK and STAT signaling molecules in immunoregulation and immune-mediated disease.Immunity. 2012; 36: 542-550
- Immunomodulatory agents for the treatment of cachexia.Curr Opin Support Palliat Care. 2014; 8: 328-333
- Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study.Eur Respir J. 1999; 14: 218-220
- Methylprednisolone induces apoptosis by interacting with the JAK/STAT pathway in HL-60 and K-562 leukemic cells.Hematology. 2012; 17: 93-99
- A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life.Gynecol Oncol. 2012; 124: 417-425
- Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review.Acta Oncol. 2013; 52: 6-17
- JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.Mol Carcinog. 2013; 52: 155-166
- NSAIDs and apoptosis.Cell Mol Life Sci. 2008; 65: 1295-1301
- Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway.Int J Colorectal Dis. 2011; 26: 13-22
- Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy.Pharmacol Res. 2012; 66: 7-18
- Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.Arterioscler Thromb Vasc Biol. 2005; 25: 1231-1236
- Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery.Crit Care Med. 2006; 34: 660-667
- Targeting tumor cell metabolism with statins.Oncogene. 2012; 31: 4967-4978
- Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway.PLoS One. 2013; 8: e62823
- The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis.Bull Hosp Jt Dis (2013). 2013; 71: S29-S32
- Interleukin-6 as a therapeutic target.Clin Cancer Res. 2015; 21: 1248-1257
- Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with Multicentric Castleman disease.Clin Cancer Res. 2015; 21: 4294-4304
- Siltuximab (CNTO 328): a promising option for human malignancies.Drug Des Devel Ther. 2015; 9: 3455-3458
- Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis.Biol Pharm Bull. 2008; 31: 1159-1163
- Tocilizumab, a proposed therapy for the cachexia of interleukin6-expressing lung cancer.PLoS One. 2014; 9: e102436
- STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells.Oncogene. 2014; 33: 1670-1679
- JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.N Engl J Med. 2012; 366: 787-798
- Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed.J Clin Oncol. 2015; ([Epub ahead of print])
Article info
Publication history
Published online: September 15, 2015
Accepted:
August 29,
2015
Received in revised form:
August 28,
2015
Received:
July 22,
2015
Identification
Copyright
© 2016 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
